Objective The Pictorial Blood Loss Assessment Chart (PBAC) is a validated tool that is used to diagnose heavy menstrual bleeding (HMB). Knowledge of the effect of its score and its relationship with outcome could have implications for using the PBAC as an outcome measurement in future HMB studies, and as a tool to evaluate the treatment effect in research and clinical practice. Our aim was to relate PBAC scores to other measures of success after endometrial ablation for HMB.
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Objective The Pictorial Blood Loss Assessment Chart (PBAC) is a validated tool that is used to diagnose heavy menstrual bleeding (HMB). Knowledge of the effect of its score and its relationship with outcome could have implications for using the PBAC as an outcome measurement in future HMB studies, and as a tool to evaluate the treatment effect in research and clinical practice. Our aim was to relate PBAC scores to other measures of success after endometrial ablation for HMB.
Design Analysis of individual patient data (IPD) of randomised controlled trials studying women with HMB.
Setting Women with HMB consulting their gynecologists.
Population or sample Individual patient data (IPD) of randomised controlled trials studying women with HMB.
Methods We included studies if they had studied secondgeneration endometrial ablation techniques and had collected PBAC scores for both baseline and follow-up. The effectiveness of treatment was scored as satisfaction or reintervention (yes/no) 12 months after treatment. We related these outcomes to the PBAC score at 12 months after treatment, and to PBAC decrease between baseline and 12 months of follow-up. Results We studied data for 900 patients included in nine studies. The median PBAC score at 12 months was 7 (0-2500). The overall satisfaction rate was 89% and the overall re-intervention rate was 7.2%. A clear association was found between absolute PBAC score at the 12-month follow-up and satisfaction (odds ratio, OR 0.16; 95% confidence interval, 95% CI 0.11-0.24) and surgical re-intervention (OR 2.3, 95% CI 1.8-2.8). A change in PBAC score was also associated with satisfaction (OR 2.0, 95% CI 1.7-2.3) and surgical re-intervention (OR 0.69, 95% CI 0.63-0.75). Both the absolute PBAC scores and the changes in score show high accuracy for both treatment outcomes.
Introduction
Heavy menstrual bleeding (HMB) is a common reason for women consulting their general practitioners and gynaecologists, and many treatment options, such as endometrial ablation, are available. HMB is defined as menstruation at regular intervals, but with excessive blood loss and duration. The Pictorial Blood Loss Assessment Chart (PBAC) is used to diagnose HMB; 1,2 however, it is unclear whether the PBAC score is also useful as an evaluation tool for the outcome of treatment. The PBAC is a semi-quantitative measurement tool. Women are instructed to count their number of used towels or tampons each day and then divide them by level of soiling. The chart is scored using the scoring system devised by Higham et al. This measurement method has a specificity and sensitivity of 80-90% when compared with the gold standard, alkaline haematin method. Most studies use a score of >150 points to define HMB. A PBAC score of 150 correlates with >80 ml of blood loss. Although 150 points is a frequently chosen cut-off point to diagnose HMB, it is uncertain whether women after treatment are satisfied with a score just below 150 points. Some women might expect amenorrhea, whereas others could be satisfied with, for example, a 50% decrease in score. In the literature, many studies use the score or decrease in PBAC score as an outcome parameter, but with no consistency in interpretation. 3 It is unknown how the women suffering from HMB evaluate these scores.
Thus, although the PBAC is considered a validated tool to diagnose HMB at a cut-off of 80 ml blood loss per cycle, it is unknown if it is a useful tool to assess the effectiveness of HMB treatment, either in a research setting or in a clinical setting. Therefore, knowledge of how these scores relate to the valuation of outcome of treatment is of great importance.
Methods

Data collection
We used raw individual patient data (IPD) of studies that were collected for an analysis coordinated by the Birmingham Clinical Trials Unit. In 2012, Daniels et al. performed a network meta-analysis comparing the effectiveness of endometrial ablation methods. For this purpose, the study group created a database consisting of IPD of randomised controlled trials (RCTs) regarding second-generation endometrial ablation for HMB. We refer to that paper for a full report of the selection procedure and data processing of participating RCTs. 4 In short, they included 19 trials published between inception and 2011. We updated this database by looking for the newest endometrial ablation studies published between May 2010 and November 2013. Three new trials were thereby added to this database.
We first selected studies that evaluated second-generation ablation in at least one randomisation arm. We only included data from patients who had undergone a secondgeneration endometrial ablation and had PBAC scores collected at baseline and follow-up. We decided to only use second-generation techniques, to reduce the heterogeneity between treatments. Besides, the use of second-generation techniques alone makes this study more applicable to practice today. Moreover, popularity can be explained by a shorter procedure and faster recovery in comparison with first-generation techniques. It seems obvious that this will influence treatment outcomes, in particular satisfaction. For this reason we chose to exclude first-generation techniques.
Data from the 12-month follow-up (the most popular follow-up time point) were used for analysis; if data from the 12-month follow-up were not available, data from the 6-month follow-up were used instead. Outcome measures were defined as satisfaction (yes/no) and surgical re-intervention (yes/no). Satisfaction and re-intervention rates were collected at the 12-month follow-up. Re-intervention was defined as either a hysterectomy or a re-ablation. Women who had a surgical re-intervention were defined as dissatisfied after their initial ablation treatment. The authors used different satisfaction scales in their papers, so the Birmingham trial unit recoded these results to a simplified scale: satisfied or dissatisfied.
Statistical analysis
We compared the PBAC scores with the effectiveness of the (second-generation ablation) treatment. Effectiveness was measured as satisfaction with the treatment outcome (yes/ no) or surgical re-intervention (yes/no). We provided boxand-whisker plots to express PBAC scores against both satisfaction (yes/no) and re-intervention (yes/no).
A logistic regression analysis, with correction for study, was performed to predict the probability of satisfaction and reintervention at the 12-month follow-up, using absolute PBAC scores at 12-month follow-up (PBAC12 m) and percentage change, i.e. [(PBACb -PBAC12 m)/PBACb] 9 100%.
We also used receiver operating characteristic (ROC) curve analysis to assess the diagnostic value of PBAC score for satisfaction or re-intervention. The area under the ROC curve (AUC) as well as the sensitivity and specificity at different PBAC scores were reported. As a sensitivity analysis, the ROC curve was also assessed using the aforementioned logistic regression models, in which we corrected for study by using the predictive probability. All statistical analyses were performed using SPSS 21.0 (IBM).
Results
Nine trials, reporting on the individual data of 900 women, met our inclusion criteria and were included in this study (Table 1) . [5] [6] [7] [8] [9] [10] [11] [12] [13] Eight different second-generation techniques were evaluated in the included studies. Study sizes varied between 30 and 209 participants. Details and baseline characteristics of the included trials are summarised in Table 1 . The overall satisfaction rate was 89% (78-98%). The overall re-intervention rate was 7.2% (0-19%). Figures 1 and 2 show the box-and-whisker plots of absolute PBAC12 m scores for both outcomes.
Logistic regression with adjustment for study gave unreliable results. The trial by Busfield et al. had a relatively small sample size and did not use satisfaction as an outcome measurement. Therefore, this study was excluded from the analyses for satisfaction.
The PBAC score at 12 months
The PBAC12 m score is strongly negatively associated with satisfaction (odd ratio, OR 0.16; 95% confidence interval, 95% CI 0.11-0.24) and positively with surgical re-intervention (OR 2.3, 95% CI 1.8-2.8).
The ROC curve for satisfaction had an AUC of 0.93 (Figure S1 ). For re-intervention, the ROC is comparable. The AUC is equal to 0.93 ( Figure S2 ). The sensitivity and specificity of different PBAC12 m scores are given in Table 2 .
Percentage of change in PBAC
The percentage change in PBAC score is also strongly positively associated with satisfaction (OR 2.0, 95% CI 1.7-2.3), and negatively associated with surgical re-intervention (OR 0.69, 95% CI 0.63-0.75). The ROC curve Data are expressed in numbers (n), years, mean (AE standard deviation), or median (min-max).
for satisfaction is shown in Figure S3 , where the AUC is 0.92. The ROC curve for re-intervention has an AUC of 0.93 ( Figure S4) . Table 3 shows different percentages of reduction in PBAC with its sensitivity and specificity.
Discussion
Main findings
Our aim was to relate PBAC scores to other measures of success of a treatment for HMB. The PBAC12 m score after treatment and percentages of PBAC score reduction are significantly associated with satisfaction and re-intervention rates, and PBAC was demonstrated to have a high accuracy for both treatment outcomes.
Strength and limitations
The PBAC has not been evaluated as a tool to assess the effectiveness of a treatment before. By combining raw individual patient data from randomised controlled trials we were able to analyse a large patient population. A limitation is that the outcome scales had to be recoded for every study to be able to combine them, as most studies reported different outcome measurement scales (e.g. satisfaction scales with 3, 4, or 5 points). Unfortunately, we could not compare the PBAC results with actual blood loss volumes after treatment because this information is lacking.
Interpretation
There is a lack of consensus about how to define and measure blood loss outcomes in HMB, and this has implications for 0  100  21  23  98  10  100  27  28  98  20  100  32  38  98  30  99  40  43  96  40  99  49  49  95  50  98  46  55  94  60  97  61  59  93  70  96  66  74  91  80  92  72  79  86  90  82  84  90  72  100  42  100  100  31 the interpretation of comparative research. Understanding the outcomes currently used to evaluate therapeutic interventions to alleviate HMB can inform the development of core outcome sets to standardise comparative research and aid in clinical interpretation. 3 Therefore, more information about the PBAC score is of utmost relevance.
The PBAC is a semi-quantitative measurement tool and it is validated for diagnosing HMB. Menstruation needs to exceed 150 points on the chart to diagnose HMB, but until now it was unclear whether the score was also associated with a treatment effect. 2 Only Pawar et al. have investigated the impact of HMB measured by PBAC score on quality of life (QoL), and found a positive correlation: the higher the PBAC score, the lower the QoL score.
14 They only studied baseline scores, however, and did not evaluate scores after treatment. Other studies confirmed the accuracy of the PBAC compared with the alkaline haematin extraction method (gold standard) for the diagnosis of HMB. Higham found that a PBAC score of >100 correlated with 80 ml of blood loss, the definition for HMB. Janssen et al. recommended a cut-off of 185 points, whereas Zakherah recommended a cut-off of 150 points. A PBAC score of >150 points is most often used as an inclusion criterion in HMB studies.
2,15, 16 Hald et al. explored the subjective perception of bleeding and the inter-individual and intra-individual variation of PBAC, and found that women scored their period as 'normal' if PBAC values were below 130 points. Nevertheless, all these aforementioned studies focused on the volume of blood loss for diagnosing HMB, not on the acceptability of the level of bleeding for women after treatment. [15] [16] [17] Thus, these PBAC levels are not comparable with those of a group of women treated for HMB. How much blood loss do women find acceptable after treatment, and how should we measure this? Although PBAC is a diagnostic tool, many studies have used the PBAC to evaluate blood loss after treatment. This is remarkable because it has never been studied for this purpose. Thus, it is actually not appropriate to base effectiveness conclusions on the PBAC measurement tool. Our study is the first study that investigated the meaning of PBAC as an outcome tool compared with the subjective satisfaction outcome, and also compared with the re-intervention rate after treatment.
But what is a good cut-off for the PBAC score after treatment? For the scoring of satisfaction we need a cut-off score that does not incorrectly describe/categorise women with high PBAC scores as satisfied. This value should also be of practical use to the clinician. Sensitivity scores of 90% or higher appear from a PBAC score of 80 points or an 80% decrease in score. Specificity scores still remain high for these values. If we take higher sensitivity scores, the PBAC scores increase above the 150-point threshold (the diagnostic value), which represents more blood loss and indicates that the treatment was not successful. Besides, with higher sensitivity scores, specificity decreases a lot, which indicates more false-positive results. Therefore, we believe that the PBAC score related to a sensitivity of 90% could be a reasonable cut-off point. For the outcome of reintervention, we would also like to have high sensitivity results, and then the values of PBAC are around 50 points or a 90% decrease in score. All these values are lower than the 'normal period', defined by Hald as <130 points. These women were probably hoping that the treatment would reduce the volume of blood loss more.
Counselling, expectations, and coping play a role as well. Therefore, if the goal of the studies is to evaluate or compare effectiveness of treatments, the use of subjective parameters as the primary outcome may not be valid or reliable.
We therefore believe that PBAC could be a meaningful outcome measure, and that the findings of this study should be used in future HMB studies. We propose that the PBAC should be used as a primary end point in studies on HMB, and should be used in clinical practice to measure the (objective) effectiveness of treatment. Of course, future studies must first validate the PBAC score after treatment.
Conclusion
The PBAC12 m scores are significantly associated with satisfaction and re-intervention rates. We propose that the PBAC should be used as a primary end point in studies on HMB as a measure to assess the effectiveness of treatment.
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